A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.

Scott DA, Boye KS, Timlin L, Clark JF, Best JH

Diabetes, obesity & metabolism3 Oct 2012Cited by 43 (Europe PMC)

PMID22958381DOI10.1111/dom.12007PepBankPUB-22958381

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, network meta-analysis estimated that liraglutide 1.2 mg lowered HbA1c by 1.01% versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c by about 1% more than placebo in a pooled comparison of trials.
Peptide
Liraglutide
Outcome
DecreaseHbA1c mean difference versus placebo, liraglutide 1.2 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · at least 24 weeksAs given in this study (human).
Measurements
HbA1c mean difference
−1.01%
liraglutide 1.2 mg vs placebo
Source sentences
Summary
-1.01% (95% CrI: -1.18 to -0.85) for liraglutide 1.2 mg
2 context sentences(design, population, supporting numbers)
Summary · context
A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo.
Summary · context
Twenty-two studies evaluating 11 049 patients were included in the network meta-analysis.
Report a problemFND-2295838101
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, network meta-analysis estimated that liraglutide 1.8 mg lowered HbA1c by 1.18% versus placebo.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c by about 1.2% more than placebo in a pooled comparison of trials.
Peptide
Liraglutide
Outcome
DecreaseHbA1c mean difference versus placebo, liraglutide 1.8 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · at least 24 weeksAs given in this study (human).
Measurements
HbA1c mean difference
−1.18%
liraglutide 1.8 mg vs placebo
Source sentences
Summary
-1.18% (95% CrI: -1.32 to -1.04) for liraglutide 1.8 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo.
Summary · context
Twenty-two studies evaluating 11 049 patients were included in the network meta-analysis.
Report a problemFND-2295838102
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, network meta-analysis found no clear HbA1c difference between exenatide once weekly and liraglutide 1.2 mg (-0.14%, credible interval including zero).
In plain wordsIn adults with type 2 diabetes, a pooled comparison found no clear HbA1c difference between liraglutide 1.2 mg and once-weekly exenatide.
Peptide
Liraglutide
Outcome
No significant changeHbA1c difference, exenatide once weekly versus liraglutide 1.2 mg
Study
n: not reported in source
Comparator
Exenatide once weekly
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · at least 24 weeksAs given in this study (human).
Measurements
HbA1c difference
−0.14%
exenatide once weekly vs liraglutide 1.2 mg
Source sentences
Summary
HbA1c differences for ExQW versus liraglutide 1.2 mg and 1.8 mg were -0.14% (95% CrI: -0.34 to 0.06) and 0.03% (95% CrI: -0.14 to 0.18), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo.
Summary · context
Twenty-two studies evaluating 11 049 patients were included in the network meta-analysis.
Report a problemFND-2295838103
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, network meta-analysis found no clear HbA1c difference between exenatide once weekly and liraglutide 1.8 mg (0.03%, credible interval including zero).
In plain wordsIn adults with type 2 diabetes, a pooled comparison found no clear HbA1c difference between liraglutide 1.8 mg and once-weekly exenatide.
Peptide
Liraglutide
Outcome
No significant changeHbA1c difference, exenatide once weekly versus liraglutide 1.8 mg
Study
n: not reported in source
Comparator
Exenatide once weekly
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · at least 24 weeksAs given in this study (human).
Measurements
HbA1c difference
0.03%
exenatide once weekly vs liraglutide 1.8 mg
Source sentences
Summary
HbA1c differences for ExQW versus liraglutide 1.2 mg and 1.8 mg were -0.14% (95% CrI: -0.34 to 0.06) and 0.03% (95% CrI: -0.14 to 0.18), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo.
Summary · context
Twenty-two studies evaluating 11 049 patients were included in the network meta-analysis.
Report a problemFND-2295838104
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, network meta-analysis estimated HbA1c 0.17% higher with liraglutide 1.2 mg than with 1.8 mg.
In plain wordsIn adults with type 2 diabetes, a pooled comparison estimated slightly less HbA1c lowering with liraglutide 1.2 mg than with 1.8 mg.
Peptide
Liraglutide
Outcome
IncreaseHbA1c difference, liraglutide 1.2 mg versus 1.8 mg
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg and 1.8 mg once daily · at least 24 weeksAs given in this study (human).
Measurements
HbA1c mean difference
0.17%
liraglutide 1.2 mg vs 1.8 mg
Source sentences
Summary
The estimated mean difference in HbA1c between liraglutide 1.2 mg and 1.8 mg was 0.17% (95% CrI: 0.02-0.30).
2 context sentences(design, population, supporting numbers)
Summary · context
A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo.
Summary · context
Twenty-two studies evaluating 11 049 patients were included in the network meta-analysis.
Report a problemFND-2295838105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.